ElliotStieglitzMD

Pediatric Hematology & Oncology • San Francisco, CA

Assistant Professor

Overview of Dr. Stieglitz

Dr. Elliot Stieglitz is a pediatric hematologist/oncologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Benioff Children's Hospital Oakland and Kaiser Permanente San Francisco Medical Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 9 years. He is one of 55 doctors at UCSF Benioff Children's Hospital Oakland and one of 24 doctors at Kaiser Permanente San Francisco Medical Center who specialize in Pediatric Hematology & Oncology. He also speaks multiple languages, including Spanish. He has more than 50 publications and over 500 citings.

Office
HDFCCC Stieglitz Lab
1450 3rd St, Room 283
San Francisco, CA 94158
Book by Phone+1(833) 314-2229

Education & Training

University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2008 - 2011
Stony Brook University Health Sciences Center School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2011 - 2026
NY State Medical License 2009 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

K08 Clinical Investigator Award NHLBI @ NIH, 2017
Individual Investigator Award American Cancer Society, 2016
Rally Grant Rally Foundation for Childhood Cancer Research, 2016
Young Investigator Award Alex's Lemonade Stand
Fellow St. Baldrick's Foundation, 2014-2016
Award Recepient Northwestern Mutual, 2015
Grant Recepient Frank A. Campini Foundation, 2014
Join now to see all

Clinical Trials

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Start of enrollment: 2018 Sep 09
Active, not recruiting
Phase 2
Expanded Access Program for Revumenib
Available
Roles: Contact

Publications & Presentations

PubMed

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
Elliot Stieglitz, Alex G Lee, Steven P Angus, Christopher Davis, Donald A Barkauskas
Cancer Discovery. 2024-09-04
Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomo...
Hong Zheng, Peng Zhao, Zhenya Tan, Wen-Mei Yu, Juwita Werner
Research Square. 2024-08-02
LNK/as a novel driver in juvenile myelomonocytic leukemia.
Astrid Wintering, Anna Hecht, Julia Meyer, Eric B Wong, Juwita Hübner
Haematologica. 2024-08-01

Journal Articles

Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm
Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature

Abstracts/Posters

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation
Elliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies
Elliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Promising New Combination of Drugs Identified to Treat Juvenile Myelomonocytic LeukemiaApril 7th, 2023
Baby Diagnosed with Rare Blood Cancer Saved by Miracle TreatmentSeptember 26th, 2019
Infant with Deadly Leukemia Saved by Drug for Adult Liver CancerSeptember 12th, 2019
Join now to see all